The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 11, 2014, Pages 3322-3331

  Paff, Michelle ^a   Alexandru Abrams, Daniela ^a   Hsu, Frank P K ^a   Bota, Daniela A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain; EGFRVIII; Glioblastoma; Therapies; Vaccine

Indexed keywords

BEVACIZUMAB; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IRINOTECAN; KEYHOLE LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 806; MONOCLONAL ANTIBODY Y10; NEW DRUG; PEPTIDE VACCINE; PEPVIII; PEPVIII KEYHOLE LIMPET HEMOCYANIN; RINDOPEPIMUT; SYNTHETIC PEPTIDE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CANCER VACCINE; DACARBAZINE; EGFR PROTEIN, HUMAN; SUBUNIT VACCINE;

ADD ON THERAPY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG TARGETING; FATALITY; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNE SYSTEM; LYMPHOCYTOPENIA; MELANOMA; NONHUMAN; PROGRESSION FREE SURVIVAL; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CAMPTOTHECIN; CANCER VACCINES; CHEMORADIOTHERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR; VACCINATION; VACCINES, SUBUNIT;

EID: 84921755907     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.983002     Document Type: Article

References (76)

1. Kohler BA, >Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA, Edwards BK. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer I May 4 2011; 103(9):714-736; PMID:21454908; http://dx.doi.org/10.1093/jnci/djr077
2. Wachtel MS, Yang S. Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era. Cancer medicine Mar 10 2014; 3(3):660-6; PMID:24610705; http://dx.doi.org/10.1002/cam4.213
3. Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, Weichselbaum RR, McCarthy BJ. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neuro-Oncol Mar 2012; 107(1):207-212; PMID:21984115; http://dx.doi.org/10.1007/s11060-011-0738-7
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med Mar 10 2005; 352(10):987-996; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330
5. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol Oct 20 2007; 25(30):4722-4729; PMID:17947719; http://dx.doi.org/10.1200/JCO.2007.12.2440
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med Jun 3 2004; 350(23):2335-2342; PMID:15175435; http://dx.doi.org/10.1056/ NEJMoa032691
7. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New Engl J Med Dec 14 2006; 355 (24):2542-2550; PMID:17167137; http://dx.doi.org/10.1056/NEJMoa061884
8. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol Feb 10 2006; 24(5):769-777; PMID:16391297; http://dx.doi.org/10.1200/JCO.2005.03.4645
9. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol Oct 1 2009; 27(28):4733-4740; PMID:19720927; http://dx.doi.org/10.1200/JCO.2008.19.8721
10. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol Jan 10 2011; 29(2):142-148; PMID:21135282; http://dx.doi.org/10.1200/JCO.2010.30.2729
11. Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res Jun 15 2011; 17(12):4119-4124; PMID:21531816; http://dx.doi.org/10.1158/1078-0432.CCR-11-0120
12. Bo L, Mork S, Kong PA, Nyland H, Pardo CA, Trapp BD. Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J neuroimmunol May 1994; 51(2):135-146; PMID:8182113; http://dx.doi.org/10.1016/0165-5728(94)90075-2
13. Stevenson PG, Austyn JM, Hawke S. Uncoupling of virus-induced inflammation and anti-viral immunity in the brain parenchyma. J Gen virol Jul 2002; 83(Pt 7):1735-1743; PMID:12075093
14. Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol Jul 2003; 3(7):569-581; PMID:12876559; http://dx.doi.org/10.1038/nri1130
15. Carrithers MD, Visintin >I, Viret C, Janeway CS, Jr. Role of genetic background in P selectin-dependent immune surveillance of the central nervous system. J Neuroimmunol Aug 2002; 129(1-2):51-57; PMID:12161020; http://dx.doi.org/10.1016/S0165-5728(02)00172-8
16. Perry VH, Andersson PB. The inflammatory response in the CNS. Neuropath appl neuro Oct 1992; 18 (5):454-459; PMID:1454134; http://dx.doi.org/10.1111/j.1365-2990.1992.tb00811.x
17. Knopf, PM, Harling-Berg CJ, Cserr HF, Basu D, Sirulnick EJ, Nolan SC, Park JT Keir G, Thompson EJ, Hickey WF, Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J Immunol 1998; 161:692-701; PMID:9670944
18. Tschen S, Stohlman SA, Ramakrishna C Hinton DR, Atkinson RD, Bergmann CC. CNS viral infection diverts homing of antibody-secreting cells from lymphoid organs to the CNS. Eur. J. Immunol. 2006; 36:603-612; PMID:16437540; http://dx.doi.org/10.1002/eji.200535123
19. Phares TW, Stholman SA, Bergmann CC. Intrathecal humoral immunity to encephalitic RNA viruses. Viruses 2013, 5:732-752; PMID:23435240; http://dx.doi.org/10.3390/v5020732
20. Brooks WH, Netsky MG, Normansell DE, Horwitz DA. Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med Dec 1 1972; 136(6):1631-1647; PMID:4345108; http://dx. doi.org/10.1084/jem.136.6.1631
21. Brooks WH, Roszman TL, Rogers AS. Impairment of rosette-forming T lymphocytes in patients with primary intracranial tumors. Cancer Apr 1976; 37 (4):1869-1873; PMID:769940; http://dx.doi.org/10.1002/1097-0142(197604)37:4%3c1869::AIDCNCR2820370435%3e3.0.CO;2-Q
22. Miescher S, Whiteside TL, de Tribolet N, von Fliedner V. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg Mar 1988; 68 (3):438-448; PMID:3257792; http://dx.doi.org/10.3171/jns.1988.68.3.0438
23. Fontana A, Hengartner H, de Tribolet N, Weber E. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol Apr 1984; 132(4):1837-1844; PMID:6607949
24. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, Fontana A. Immunosuppression and transforming growth factor-b in glioblastoma. Preferential production of transforming growth factor-b 2. J Immunol Nov 15 1989; 143(10):3222-3229; PMID:2809198
25. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE 2nd, Bigner DD, Dranoff G, Sampson JH. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res Mar 15 2006; 66(6):3294-3302; PMID:16540683; http://dx.doi.org/10.1158/0008-5472.CAN-05-3773
26. El Andaloussi A, Lesniak MS. An increase in CD4CCD25 CFOXP3 C regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro-oncology Jul 2006; 8 (3):234-243; PMID:16723631; http://dx.doi.org/10.1215/15228517-2006-006
27. Thornton AM, Shevach EM. CD4CCD25C immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med Jul 20 1998; 188(2):287-296; PMID:9670041; http://dx.doi.org/10.1084/jem.188.2.287
28. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Sawaya R, et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clinical Cancer Res Jan 15 2010; 16 (2):461-473; PMID:20068105; http://dx.doi.org/10.1158/1078-0432.CCR-09-1983
29. Backer O, Arden KC, Borretti M, Vantomme V, De Smet C, Czekay S, Viars CS, De Plaen E, Brasseur F, Chomez P, et al. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res 1999; 59:3157-65; PMID:10397259
30. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med Sep 1 1995; 182(3):689-698; PMID:7544395; http://dx.doi.org/10.1084/jem.182.3.689
31. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res Feb 15 2005; 11(4):1462-1466; PMID:15746047; http://dx.doi.org/10.1158/1078-0432.CCR-04-1737
32. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Re Dec 1 1995; 55(23):5536-5539; PMID:7585629
33. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem May 15 1990; 265(14):7709-7712; PMID:2186024
34. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee WK, Huang HS. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem Oct 11 1996; 271(41):25639-25645; PMID:8810340; http://dx.doi.org/10.1074/jbc.271.41.25639
35. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, Bigner DD. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res Dec 15 1990; 50 (24):8017-8022; PMID:2253244
36. Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, Friedman HS, Kwatra MM, Bigner SH, Bigner DD. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A Jun 1990; 87 (11):4207-4211; PMID:1693434; http://dx.doi.org/10.1073/pnas.87.11.4207
37. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumorassociated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res Sep 15 1997; 57(18):4130-4140; PMID:9307304
38. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol May 2008; 10(5):619-624; PMID:18425114; http://dx.doi.org/10.1038/ncb1725
39. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol May 2007; 170(5):1445-1453; PMID:17456751; http://dx.doi. org/10.2353/ajpath.2007.070011
40. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A Aug 2 1994; 91(16):7727-7731; PMID:8052651; http://dx.doi.org/10.1073/pnas.91.16.7727
41. Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS, Bigner DD. Epidermal growth factor ligand-independent, unregulated, celltransforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ Oct 1995; 6(10):1251-1259; PMID:8845302.
42. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res Nov 1 1996; 56(21):5079-5086; PMID:8895767
43. Pedersen MW, Tkach V, Pedersen N, Berezin V, Poulsen HS. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer JInt du Cancer Feb 20 2004; 108(5):643-653; PMID:14696090; http://dx.doi.org/10.1002/ijc.11566
44. Lammering G, Valerie K, Lin PS, Hewit TH, Schmidt-Ullrich RK. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol Sep 2004; 72(3):267-273; PMID:15450724; http://dx.doi.org/10.1016/j.radonc.2004.07.004
45. Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, Lin PS, Mikkelsen RB, Schmidt-Ullrich RK. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clin Cancer Res Oct 1 2004; 10(19):6732-6743; PMID:15475464; http://dx.doi.org/10.1158/1078-0432.CCR-04-0393
46. Montgomery RB, Guzman J, O'Rourke DM, Stahl WL. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters b-tubulin isotype expression. J Biol Chem Jun 9 2000; 275(23):17358-17363; PMID:10749863; http://dx.doi.org/10.1074/jbc.M000966200
47. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol Jun 1 2007; 25(16):2288-2294; PMID:17538175; http://dx.doi.org/10.1200/JCO.2006.08.0705
48. Wikstrand CJ, Stanley SD, Humphrey PA, Pegram CN, Archer GE, Kurpad S, Shibuya M, Bigner DD. Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas. J Neuroimmunol Jul 1993; 46(1-2):165-173; PMID:8360327; http://dx.doi.org/10.1016/0165-5728(93)90246-U
49. Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, Hale LP, Small C, Dranoff G, Friedman AH, et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A Jun 20 2000; 97(13):7503-7508; PMID:10852962; http://dx.doi.org/10.1073/pnas.130166597
50. Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wildtype EGFR. Cancer Res Jul 15 2001;61(14):5355-5361; PMID:11454674
51. Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res Jul 15 2001; 61(14):5349-5354; PMID:11454673
52. Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A. Jan 21 2003; 100(2):639-644; PMID:12515857; http://dx.doi.org/10.1073/pnas.232686499
53. Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC, et al. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer J Int du Cancer Mar 20 2002; 98(3):398-408; PMID:11920591; http://dx.doi.org/10.1002/ijc.10189
54. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res Sep 15 2003; 9(11):4247-4254; PMID:14519652
55. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9:271-296; PMID:1910679; http://dx.doi.org/10.1146/annurev.iy.09.040191.001415
56. Liau LM, Black KL, Prins RM, Sykes SN DiPatre PL, Cloughesy TF, Becker DP, Bronstein JM. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg Jun 1999; 90(6):1115-1124; PMID:10350260; http://dx.doi.org/10.3171/jns.1999.90.6.1115
57. Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, Pracyk JB, Friedman AH, Friedman HS, Bigner DD, et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFRtyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res Nov 2002; 8(11):3496-3502; PMID:12429640
58. Wu AH, Xiao J, Anker L, Hall WA, Gregerson DS, Cavenee WK, Chen W, Low WC. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neuro-oncol Jan 2006; 76(1):23-30; PMID:16155724; http://dx.doi.org/10.1007/s11060-005-3280-7
59. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE 2nd, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther Oct 2009; 8(10):2773-2779; PMID:19825799; http://dx.doi.org/10.1158/1535-7163.MCT-09-0124
60. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE 2nd, McLendon RE, Mitchell DA, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol Nov 1 2010; 28(31):4722-4729; PMID:20921459; http://dx.doi.org/10.1200/JCO.2010.28.6963
61. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, et al. Greater chemother-apy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-oncol Mar 2011; 13(3):324-333; PMID:21149254; http://dx.doi.org/10.1093/neuonc/noq157
62. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science Oct 25 2002; 298(5594):850-854; PMID:12242449; http://dx.doi. org/10.1126/science.1076514
63. Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA, Theofilopoulos AN. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest Jul 2002; 110(2):185-192; PMID:12122110; http://dx.doi.org/10.1172/JCI0215175
64. Lai RK RL, Reardon DA. Long-term follow-up of ACT III: A Phase II trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma. Neuro-oncol 2011 2011; 13(suppl 3):iii34-iii40.
65. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res Mar 15 2011; 17(6):1603-1615; PMID:21135147; http://dx.doi.org/10.1158/1078-0432.CCR-10-2563
66. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S, Goldfinger D, Ng H, Irvin D, Yu JS. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res Jul 15 2008; 68(14):5955-5964; PMID:18632651; http://dx.doi.org/10.1158/0008-5472.CAN-07-5973
67. Wheeler CJ. Dendritic cell vaccines to combat glioblastoma. Expert Review Neurother Apr 2010; 10(4):483-486; PMID:20367199; http://dx.doi.org/10.1586/ern.10.26
68. Mailliard RB, Wankowics-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P. Alpha-type 1 polarized dendritic cells: A novel immunization tool with optimized CTLinducing activity. Cancer Res 2004; 64:5934-5937; PMID:15342370; http://dx.doi.org/10.1158/0008-5472.CAN-04-1261
69. Kalinski P, Schuitemaker JHN, Hilkens CMU Wierenga EA, Kapsenberg ML. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 Inducers: decreased ability of mature dendritic cells to produce IL-12 during interaction with Th cells. J Immunol 1999; 162:3231-3231; PMID:10092774
70. Okada H, Kalinski P, Ueda A, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK et al. Induction of CD8 C T cell responses against novel glioma associated antigen peptides and clinical activity by vaccinations with a - type 1 polarized dendritic cells and polyincosinci-polycytidylic acid stabilized by Lycine and carboxymethylcellulose in patients with recurrent Malignant Glioma. J Clin Onc 2011; 29.3:330-336; PMID:21149657; http://dx.doi.org/10.1200/JCO.2010.30.7744
71. Akiyama Y, Oshita C, Kume A, Iizuka A, Miyata H, Komiyama M, Ashizawa T, Yagoto M, Abe Y, Mitsuya K et al. Alpha Type 1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. Cancer 2012; 12:623; PMID:23270484
72. Ishikawa I., Yoshihiro, M, Tetsuya, Y., Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M et al. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalinfixed tumor vaccine for newly-diagnosed glioblastoma. J Neurosurg 2014; 121:543-553; PMID:24995786; http://dx.doi.org/10.3171/2014.5.JNS132392
73. Terasaki M, Shibui S, Narita Y, Fujimaki T, Aoki T, Kajiwara K, Sawamura Y, Kurisu K, Mineta T, Yamada A et al. Phase I trial of a personalized peptide vaccine for patients positive for humanleukocyte antigen a24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 2010; 29:337-344; PMID:21149665; http://dx.doi.org/10.1200/JCO.2010.29.7499
74. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL et al. Phase I study of single agent sntiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28.19:3167-3175; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609
75. Iwai Y, Ishida M, Tanaka Y Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from the host immune system and tumor immunotherapy by PD-L1 blockade. Prc Natl Acad Sci USA 2002; 99:12293-12297; PMID:12218188; http://dx.doi.org/10.1073/pnas.192461099
76. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W et al. B7-H1 blockade augments T cell immunotherapy for squamous cell carcinoma. Cancer Res 2003; 63:6501-6505; PMID:14559843